Biofluid spectroscopy is an emerging technology in the field of clinical investigation, providing a simple way to extract diagnostic and observational information from easy to acquire samples. Infrared spectroscopy is well suited to analyse a large range of biofluid samples, including blood and its derivatives, due to flexible sampling modes and high sensitivity to subtle biological changes. As the technology advances towards the clinic, factors influencing successful clinical translation are becoming apparent. Here, we provide a tutorial for effective biofluid spectroscopy study design, discussing sample and instrument parameters, as well as clinical considerations. The aim is to present the current understanding of clinical translation in the field of biofluid spectroscopy, and to facilitate other clinical applications to advance to the clinic. image
Pancreatic cancer claims over 460,000 victims per year. The carbohydrate antigen (CA) 19-9 test is the blood test used for pancreatic cancer’s detection; however, its levels can be raised in symptomatic patients with other non-malignant diseases, or with other tumors in the surrounding area. Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy has demonstrated exceptional potential in cancer diagnostics, and its clinical implementation could represent a significant step towards early detection. This proof-of-concept study, investigating the use of ATR-FTIR spectroscopy on dried blood serum, focused on the discrimination of both cancer versus healthy control samples, and cancer versus symptomatic non-malignant control samples, as a novel liquid biopsy approach for pancreatic cancer diagnosis. Machine learning algorithms were applied, achieving results of up to 92% sensitivity and 88% specificity when discriminating between cancers (n = 100) and healthy controls (n = 100). An area under the curve (AUC) of 0.95 was obtained through receiver operating characteristic (ROC) analysis. Balanced sensitivity and specificity over 75%, with an AUC of 0.83, were achieved with cancers (n = 35) versus symptomatic controls (n = 35). Herein, we present these results as demonstration that our liquid biopsy approach could become a simple, minimally invasive, and reliable diagnostic test for pancreatic cancer detection.
In recent years, the diagnosis of brain tumors has been investigated with attenuated total reflection ‐ Fourier transform infrared (ATR‐FTIR) spectroscopy on dried human serum samples to eliminate spectral interferences of the water component, with promising results. This research evaluates ATR‐FTIR on both liquid and air‐dried samples to investigate “digital drying” as an alternative approach for the analysis of spectra obtained from liquid samples. Digital drying approaches, consisting of water subtraction and least‐squares method, have demonstrated a greater Random Forest (RF) classification performance than the air‐dried spectra approach when discriminating cancer versus control samples, reaching sensitivity values higher than 93.0% and specificity values higher than 83.0%. Moreover, quantum cascade laser infrared (QCL‐IR) based spectroscopic imaging is utilized on liquid samples to assess the implications of a deep‐penetration light source on disease classification. The RF classification of QCL‐IR data has provided sensitivity and specificity amounting to 85.1% and 75.3% respectively.
Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes and limiting disease progression. Screening of average-risk individuals is essential for detecting tumors at an earlier, more treatable stage. However, adherence to current screening programs remains suboptimal. Liquid biopsies represent a promising alternative to stool-based tests and may play a key role in optimizing colorectal cancer detection and diagnostic pathways. In this study, 957 patients were recruited across various clinical sites in the United States: 48 with colorectal cancer, 157 with advanced precancerous lesions (APL), 331 with nonadvanced lesions, and 421 with a negative colonoscopy diagnosis. Blood was obtained from patients either prior to scheduled colonoscopy or before surgical resection and any anticancer therapies. Streck plasma samples were analyzed by the Dxcover Liquid Biopsy Platform and classified using machine learning algorithms. When colorectal cancer was classified against all other groups, the ROC curve generated an AUC value of 0.95, and test sensitivity and specificity were 90% and 89%, respectively. The diagnostic model accurately predicted 75% of stage I (3/4), 100% of stage II (15/15), 93% of stage III (14/15), and 100% of stage IV (6/6) colorectal cancers. For the advanced colorectal neoplasia model, 29% of APL were detected. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer. Prevention Relevance: Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer.